Leerink raised its price target for NPS Pharmaceuticals citing increased confidence on the commercial potential of Natpara for the treatment of hypoparathyroidism. The firm calls NPS a top pick for the second half of 2013 and reiterates an Outperform rating on the stock.
- Health Care Industry
- Investment & Company Information
- NPS Pharmaceuticals